Meyka Pro banner
AnaptysBio, Inc.

AnaptysBio, Inc. Fundamental Analysis (NASDAQ: ANAB)

ANAB●NASDAQ
HealthcareBiotechnology
$46.63
$0.77(1.62%)
U.S. Market opens in 34h 6m

AnaptysBio, Inc. Fundamental Analysis (NASDAQ: ANAB)

AnaptysBio, Inc. (NASDAQ: ANAB) shows moderate financial fundamentals with a PE ratio of 7.31, profit margin of 96.30%, and ROE of 9.07%. The company generates $0.2B in annual revenue with weak year-over-year growth of 1.57%.

Key Strengths

Operating Margin34.62%
Cash Position10.99%
PEG Ratio-0.00
Current Ratio8.40

Areas of Concern

ROE9.07%
We analyze ANAB's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 69.8/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.

Fundamental Health Score

C+
69.8/100

We analyze ANAB's fundamental strength across five key dimensions:

Efficiency Score

Excellent

ANAB demonstrates superior asset utilization.

ROA > 10%
60.08%

Valuation Score

Excellent

ANAB trades at attractive valuation levels.

PE < 25
7.31
PEG Ratio < 2
-0.00

Growth Score

Moderate

ANAB shows steady but slowing expansion.

Revenue Growth > 5%
1.57%
EPS Growth > 10%
91.02%

Financial Health Score

Excellent

ANAB maintains a strong and stable balance sheet.

Debt/Equity < 1
0.60
Current Ratio > 1
8.40

Profitability Score

Moderate

ANAB maintains healthy but balanced margins.

ROE > 15%
9.07%
Net Margin ≥ 15%
96.30%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is ANAB Expensive or Cheap?

P/E Ratio

ANAB trades at 7.31 times earnings. This suggests potential undervaluation.

7.31

PEG Ratio

When adjusting for growth, ANAB's PEG of -0.00 indicates potential undervaluation.

-0.00

Price to Book

The market values AnaptysBio, Inc. at 66.67 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

66.67

EV/EBITDA

Enterprise value stands at 19.60 times EBITDA. This signals the market has high growth expectations.

19.60

How Well Does ANAB Make Money?

Net Profit Margin

For every $100 in sales, AnaptysBio, Inc. keeps $96.30 as profit after all expenses.

96.30%

Operating Margin

Core operations generate 34.62 in profit for every $100 in revenue, before interest and taxes.

34.62%

ROE

Management delivers $9.07 in profit for every $100 of shareholder equity.

9.07%

ROA

AnaptysBio, Inc. generates $60.08 in profit for every $100 in assets, demonstrating efficient asset deployment.

60.08%

Following the Money - Real Cash Generation

Operating Cash Flow

AnaptysBio, Inc. produces operating cash flow of $35.75M, showing steady but balanced cash generation.

$35.75M

Free Cash Flow

AnaptysBio, Inc. generates strong free cash flow of $35.75M, providing ample flexibility for dividends, buybacks, or growth.

$35.75M

FCF Per Share

Each share generates $1.20 in free cash annually.

$1.20

FCF Yield

ANAB converts 2.59% of its market value into free cash.

2.59%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

7.31

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

66.67

vs 25 benchmark

P/S Ratio

Price to sales ratio

7.22

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.60

vs 25 benchmark

Current Ratio

Current assets to current liabilities

8.40

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

9.07

vs 25 benchmark

ROA

Return on assets percentage

0.60

vs 25 benchmark

ROCE

Return on capital employed

0.23

vs 25 benchmark

How ANAB Stacks Against Its Sector Peers

MetricANAB ValueSector AveragePerformance
P/E Ratio7.3130.24 Better (Cheaper)
ROE906.99%540.00% Excellent
Net Margin96.30%-2322.00% (disorted) Strong
Debt/Equity0.600.08 Weak (High Leverage)
Current Ratio8.405.59 Strong Liquidity
ROA60.08%-17516.00% (disorted) Strong

ANAB outperforms its industry in 5 out of 6 key metrics, particularly excelling in ROE, but lagging in Debt/Equity.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews AnaptysBio, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

207.32%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

34.77%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

236.69%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ